Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 1/2 2Phase 1 2

Status

Completed 4Terminated 2Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 1Gynecologic 1

Conditions

Ovarian Neoplasms 1Lymphoma 1Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

pembrolizumab 73Carboplatin 60Cyclophosphamide 59Nivolumab 52Paclitaxel 47Gemcitabine 44Cisplatin 43Dexamethasone 41Radiotherapy 36Rituximab 32Capecitabine 32Bevacizumab 29Docetaxel 28fludarabine 27atezolizumab 26Cytarabine 26avelumab 24Trastuzumab 23Oxaliplatin 23Lenalidomide 23Cetuximab 23venetoclax 22Ipilimumab 22Fluorouracil 22Azacitidine 22Temozolomide 21130-nm albumin-bound paclitaxel 21fludarabine phosphate 20Filgrastim 20Bortezomib 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Terminated × 1-dodecylpyridoxal × Clear all
NCT05261490 2024-11-19

Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer

Pfizer

Phase 1/2 Terminated
10 enrolled 21 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00785798 2022-04-04

Vorinostat and Pegylated Liposomal Doxorubicin in Relapsed or Refractory Lymphomas

Yale University

Phase 1/2 Terminated
17 enrolled 4 charts
Lymphoid

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡